InvestmentMay 29, 2026, 05:07 PM
Calidi Biotherapeutics Amends Warrant for 17.39M Shares to Investor
AI Summary
Calidi Biotherapeutics, Inc. issued an amended and restated warrant on May 28, 2026, to an accredited investor, allowing the purchase of up to 17,391,304 unvested common stock shares at an exercise price of $0.23. This amendment modifies a previous warrant from May 6, 2026. Key changes include conditioning the warrant's exercise on stockholder approval, increasing the Minimum Vesting Acquisition Amount from $500,000 to $1,000,000, and extending the Vesting Termination Date to September 30, 2026.
Key Highlights
- Calidi Biotherapeutics issued an amended and restated warrant for up to 17,391,304 unvested shares of common stock.
- The warrant has an exercise price of $0.23 per share and was issued to an accredited investor in a private placement.
- Exercise of the warrant and issuance of shares are now conditioned on stockholder approval.
- The Minimum Vesting Acquisition Amount increased from $500,000 to $1,000,000.
- The Vesting Termination Date was extended from July 8, 2026, to September 30, 2026.
- The issuance relies on Section 4(a)(2) of the Securities Act and Rule 506(b).
Price Impact
More from CLDI